(BFRG) Bullfrog AI Holdings, Inc. Company Overview

What does BullFrog AI Holdings do?

BullFrog AI Holdings, Inc. is a small, commercial-stage life-sciences technology company listed on the Nasdaq Capital Market under BFRG. It applies artificial intelligence and machine learning to biomedical data, with the goal of improving target identification, drug development decisions, patient stratification, and the probability that therapeutic programs produce useful clinical results. The company reports as one operating segment rather than separate software and biotechnology divisions.

Which products and assets define the company?

The core analytical engine is bfLEAP, technology originally developed at the Johns Hopkins University Applied Physics Laboratory and licensed to BullFrog. The broader commercial stack now includes BullFrog Data Networks for integrated biomedical-data analysis, bfPREP for cleaning and harmonizing fragmented datasets, and bfARENAS for scenario-based portfolio and clinical-trial decisions. The company also holds rights to early-stage drug assets, including mebendazole formulations for glioblastoma and a Beta2-spectrin siRNA program. The 2025 Form 10-K is the most complete official description of these platforms, licenses, and development programs.

How does BullFrog AI make money?

BullFrog’s model has two related but economically different paths. The first is commercial analytics: a customer supplies a biomedical problem and relevant data, BullFrog prepares and analyzes the information, and the engagement can generate collaboration fees or milestone payments. The second path is asset-oriented: BullFrog acquires or licenses a drug program, uses its technology to identify a better development strategy or responsive patient subgroup, advances the program, and seeks to monetize it through a sale, sublicense, milestones, or royalties.

Why is the March 2026 pharmaceutical agreement important?

On March 30, 2026, BullFrog announced a commercial feasibility agreement with a top-five global pharmaceutical company by 2025 revenue. The work uses bfLEAP to identify and prioritize novel targets in major depressive disorder, includes milestone payments tied to deliverables, and gives the customer an option for exclusive rights to a selected target. The customer name and total contract value were not disclosed, so the agreement should be read as commercial validation rather than as evidence of material near-term revenue. The official commercial agreement announcement describes the scope and exclusivity option.

What limits revenue quality today?

The 2025 revenue base was extremely small and concentrated. Cost of collaboration revenue was $94,778, leaving gross profit of $21,892. In addition, the filing states that the consideration associated with the recognized collaboration revenue was non-cash. BullFrog had not recognized revenue under its June 2025 Sygnature Discovery marketing collaboration by year-end. For researchers, the central question is therefore not whether the company has a conceptually attractive revenue model, but whether it can convert pilot work into cash-paying, repeat, and expanding contracts.

What did BullFrog AI’s latest quarter show?

The latest filed financial period is the quarter ended March 31, 2026. BullFrog reported no revenue and no gross profit, but operating expenses declined year over year. The quarter was defined more by financing than operations: equity sales increased cash and restored reported stockholders’ equity above the Nasdaq threshold. The company’s Q1 2026 Form 10-Q provides the period’s complete financial statements.

Did expense discipline improve?

From Johns Hopkins technology to an integrated pharma AI platform

BullFrog’s history is best understood as a sequence of licensing, public-market financing, product expansion, and commercial validation. The company did not build a large proprietary drug portfolio first and add software later. Instead, it began with licensed analytical technology, added external biomedical datasets and drug rights, and then broadened the commercial workflow around data preparation, analysis, and decisions.

Which turning points still shape the strategy?

1. 2017
   BullFrog AI, Inc. was founded, establishing the operating concept around machine learning for drug development.
2. 2018
   The company obtained an exclusive worldwide license to JHU-APL technology underlying bfLEAP, creating both differentiation and continuing royalty obligations.
3. 2020
   BullFrog AI Holdings was incorporated in Nevada and became the public-company parent structure.
4. 2022
   New licenses expanded the analytical intellectual property and added mebendazole and Beta2-spectrin siRNA development rights.
5. 2023
   The Nasdaq IPO supplied public capital, while the Lieber Institute relationship added rich brain-related datasets and commercialization rights.
6. 2025
   BullFrog reported its first collaboration revenue, introduced bfPREP, and began a joint marketing collaboration with Sygnature Discovery.
7. 2026
   bfARENAS completed the stated end-to-end workflow, the top-five pharmaceutical agreement validated enterprise demand, and a new commercial team was appointed to pursue scale.

What gives BullFrog AI a competitive advantage?

BullFrog’s claimed advantage is not simply “using AI.” Its differentiation rests on the ability to handle complex, imbalanced biomedical datasets, combine supervised and unsupervised methods, expose relationships without requiring a predefined hypothesis, and present decisions in an explainable workflow. The company also has access to licensed patents, proprietary algorithm libraries, and specialized datasets. These resources may reduce the time required to prepare data and may help pharmaceutical teams test target, biomarker, and trial-design hypotheses more systematically.

How durable is the intellectual-property position?

The platform’s roots in JHU-APL technology are strategically useful, but the economics are not cost-free. The 2022 license carries an 8% royalty on external service net sales, 3% on internal drug projects using the technology, tiered sublicensing fees starting at 50% and declining to 25%, and minimum annual royalties of $300,000 from 2024 onward. At December 31, 2025, BullFrog had accrued the full $300,000 minimum annual royalty, which remained uninvoiced and unpaid at filing. This is a useful case-study distinction: licensed intellectual property can create barriers and credibility while also reducing future gross economics and creating fixed obligations before scale.

Who competes with BullFrog AI, and where is its market position?

Competition operates on several levels. Large pharmaceutical companies can build internal data-science teams. Established contract research and informatics providers can bundle analytics with broader discovery services. Better-capitalized AI drug-discovery companies can invest more heavily in proprietary datasets, foundation models, laboratories, and internal pipelines. Academic institutions and public research programs can also produce competing methods. BullFrog’s own filing emphasizes that many rivals have substantially greater resources for R&D, clinical trials, regulatory approvals, manufacturing, and recruiting.

Where can a small specialist compete?

A specialist can win when a customer values flexibility, explainability, multimodal-data integration, and access to senior scientific attention. BullFrog does not need to outspend every AI-drug-discovery rival if it can become a trusted analytical layer inside larger partners’ programs. The June 2026 appointment of commercial executives with enterprise technology and biotechnology backgrounds shows that management views go-to-market capability as the next bottleneck. The official commercial leadership announcement frames the product set as one integrated pharmaceutical AI platform.

How financially strong is BullFrog AI?

BullFrog’s financial strength is best described as improved but still dependent on capital markets. At March 31, 2026, cash and cash equivalents were $5.080M, restricted cash was $0.105M, total assets were $5.539M, total liabilities were $0.652M, and stockholders’ equity was $4.887M. The company had no conventional long-term debt on the balance sheet, but it had an accumulated deficit of $24.885M and continued to consume cash in operations.

What did financing accomplish, and what did it cost?

During Q1 2026, BullFrog received approximately $1.9M of net proceeds from selling 2,176,604 shares under its at-the-market program at an average price of about $0.91. It also sold 4,852,318 shares under the Lincoln Park equity-line facility for gross proceeds of approximately $5.9M at an average price of about $1.21; $3.3M was collected on April 1 and therefore appeared as uncollected proceeds at quarter-end. Common shares outstanding increased from 11,418,183 at December 31, 2025 to 18,447,105 at March 31, 2026, a 61.6% increase in three months.

Management stated in April 2026 that financing supported runway into late 2027, while the Q1 filing said cash was expected to fund planned operations for at least one year beyond the filing date, subject to assumptions. Nasdaq confirmed that BullFrog had regained the $2.5M minimum stockholders’ equity requirement on April 21, 2026, but imposed one year of mandatory monitoring. The official Nasdaq compliance announcement explains that status.

Who owns BullFrog AI stock, and how is it governed?

BullFrog has one vote per common share and no other voting class was outstanding at the April 20, 2026 record date. Founder, Chairman, and CEO Vininder Singh remains the most influential disclosed insider. The ownership picture is complicated by rapid share issuance: the March 1 beneficial-ownership table was based on 12,664,387 common shares, while the proxy reported 18,530,865 common shares outstanding by April 20.

How much influence does the founder retain?

The 2026 proxy statement also shows four annual director nominees and three standing committees. Singh serves as both CEO and chair. The board states that combining the roles benefits daily operations and strategic perspective, while the audit committee oversees financial, regulatory, and cybersecurity risk.

A June 2026 Form 8-K disclosed that Singh’s annual base salary increased from $400,000 to $600,000 and his target annual bonus became up to 50% of base salary. For a company with $116,670 of FY2025 revenue, executive compensation, equity incentives, and measurable commercial milestones deserve close governance scrutiny.

Commercial opportunities, operating KPIs, and material risks

BullFrog’s upside is tied to converting its technical assets into repeatable enterprise demand. The March 2026 pharmaceutical agreement can become more valuable if it reaches milestones, expands to additional research programs, or produces exclusive target rights. The integrated bfPREP-bfLEAP-bfARENAS workflow may also increase the addressable scope of each customer engagement. The official bfARENAS announcement positions the product as the decision layer completing that workflow.

Which growth drivers matter most?

What risks could weaken the story?

Why does BullFrog AI’s business model matter for valuation?

A conventional DCF is difficult for BullFrog because the current financial base does not yet provide a stable revenue-growth, margin, or reinvestment pattern. FY2025 revenue was $0.117M, Q1 2026 revenue was zero, and operating cash use remained substantial. A valuation model therefore depends less on extrapolating historical sales and more on explicit scenarios for contract wins, average project value, milestone conversion, platform gross margin after royalties, operating expense scale, and future share issuance.

Which variables should a researcher model?

What is the key takeaway from BullFrog AI analysis?

BullFrog matters as a case study in how a micro-cap life-sciences company tries to commercialize licensed AI technology across both services and therapeutic assets. The integrated product architecture, specialized biomedical focus, academic licenses, and 2026 pharmaceutical agreement provide real strategic substance. Yet the financial evidence remains early: revenue is minimal, cash burn is high relative to the balance sheet, licensing obligations are meaningful, and recent liquidity improvement came primarily from issuing shares.